Short answer: yes. “Ozempic” is a brand name for semaglutide, a synthetic peptide - a chain of 31 amino acids modelled on the natural gut hormone glucagon-like peptide-1 (GLP-1). Pharmacologically it is a GLP-1 receptor agonist. The molecule is a peptide; the approved medicine is a separate legal and intended-use category from research-use-only material.
Few molecules have done more to put the word “peptide” into everyday conversation than the GLP-1 class. People searching “is Ozempic a peptide” are usually trying to connect two things they keep hearing about - the headline weight and metabolic drugs, and the broader category of research peptides. The connection is real, but the details matter. This explainer keeps it in plain English and in a research-literacy frame.
Plain-English summary. A peptide is a short chain of amino acids. Semaglutide (sold under brand names including Ozempic and Wegovy) is exactly that - an engineered peptide that imitates the body’s own GLP-1 hormone. It is an approved medicine, manufactured and licensed for human therapeutic use under regulators such as the FDA and the EMA. New-U does not sell it and does not provide medical or dosing advice. We supply research-use-only reagents.
A peptide is a short chain of amino acids joined by peptide bonds - chemically the same building blocks as proteins, just shorter. Insulin is a peptide. Many of the body’s own signalling hormones are peptides. When researchers talk about “peptides” as a category, they mean these compact signalling molecules that bind specific receptors and trigger a defined biological response. For the longer version, see our explainer on what peptides are.
GLP-1 is an incretin - a hormone released by cells in the gut after you eat. The peer-reviewed literature indexed on PubMed describes several coordinated effects: it stimulates glucose-dependent insulin secretion, suppresses glucagon, slows the rate at which the stomach empties, and acts on appetite-related signalling in the brain. The catch with native GLP-1 is that the body degrades it within minutes via the enzyme DPP-4, which makes the natural hormone impractical as a long-acting therapy.
Semaglutide is a GLP-1 receptor agonist: an engineered peptide designed to bind the same receptor as natural GLP-1 but resist rapid breakdown, so a single dose lasts far longer. That structural engineering - amino-acid substitutions plus a fatty-acid chain that promotes albumin binding - is why it became a once-weekly therapy. The U.S. National Library of Medicine’s DailyMed label database and the regulator listings are the authoritative primary sources for any approved product’s indications and status.
The naming, decoded. “Semaglutide” is the compound (an International Nonproprietary Name). “Ozempic” and “Wegovy” are brand names for licensed products containing it. “GLP-1 receptor agonist” is the pharmacological class. All three describe the same kind of peptide from different angles.
The class is broader than one compound. Some agents target the GLP-1 receptor alone; others are dual (GIP + GLP-1) or triple (GIP + GLP-1 + glucagon) agonists. In research-compound shorthand these are written generically - you will see codes such as GLP-1 RC-S vs GLP-1 RC-T for the dual-agonist comparison, and GLP-1 RC-R for the triple-agonist (retatrutide / LY3437943) case - precisely because research material is a different category from licensed medicine. The mechanistic literature for the whole family is catalogued on PubMed and trial registrations on ClinicalTrials.gov.
A large share of interest in this topic comes from weight-related searches. The honest, research-literate framing is this: GLP-1 receptor agonists are peptides, and the metabolic-research literature on the receptor is extensive, but body-composition outcomes in humans are a clinical-medicine question governed by approved products and licensed prescribers - not something a research-reagent supplier can advise on. New-U does not provide dosing, protocols, or human-use guidance, and nothing here is medical advice. If you want the regulatory map of which peptides are approved versus investigational, read Peptides & the FDA.
This is the distinction that actually matters for anyone reading about peptides online:
The peptide chemistry can overlap between these worlds; the legal and intended-use category does not. Conflating them is the single most common mistake in online peptide discussion. See our explainer on whether peptides are legal for the jurisdiction-by-jurisdiction picture.
Is Ozempic a peptide?
Yes - it is a brand of semaglutide, a 31-amino-acid synthetic peptide and a GLP-1 receptor agonist. General information, not medical advice.
Is insulin a peptide too?
Yes. Insulin is one of the best-known peptide hormones, which is why peptide therapeutics are a long-established pharmaceutical category, not a new fad.
Can I buy Ozempic from New-U?
No. New-U supplies research-use-only compounds with a CoA, not approved medicines, and gives no dosing or medical guidance.
Why do research listings use codes instead of drug names?
Because research material is a separate category from licensed medicine; generic research codes avoid implying human-therapeutic use.
External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalog